Interventions for treating oral leukoplakia to prevent oral cancer

Cochrane Database of Systematic Reviews

Volumn 2016, Issue 7, 2016, Pages

  Lodi, Giovanni ^a   Franchini, Roberto ^a   Warnakulasuriya, Saman ^b   Varoni, Elena Maria ^a   Sardella, Andrea ^a   Kerr, Alexander R ^c   Carrassi, Antonio ^a   Macdonald, L C I ^d   Worthington, Helen V ^d  

^a UNIVERSITY OF MILAN   (Italy)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c NEW YORK UNIVERSITY COLLEGE OF DENTISTRY   (United States)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; AMINOLEVULINIC ACID; ASPARTATE AMINOTRANSFERASE; BETA CAROTENE; BIOLOGICAL MARKER; BLEOMYCIN; BOWMAN BIRK INHIBITOR; CAROTENOID; CELECOXIB; CELL NUCLEUS ANTIGEN; CHOLESTEROL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FENRETINIDE; GREEN TEA EXTRACT; HERBACEOUS AGENT; ISOTRETINOIN; KETOROLAC; LYCOPENE; NONSTEROID ANTIINFLAMMATORY AGENT; PIOGLITAZONE; PLACEBO; PROTEINASE; RETINOID; RETINOL; SULINDAC; TRIACYLGLYCEROL;

ABDOMINAL PAIN; ABSENCE OF SIDE EFFECTS; CANCER INCIDENCE; CANCER PREVENTION; CANCER RECURRENCE; CANCER RISK; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CLINICAL ASSESSMENT; CLINICAL FEATURE; COCHRANE LIBRARY; CONJUNCTIVITIS; CONTROLLED CLINICAL TRIAL (TOPIC); DIARRHEA; DISEASE FREE SURVIVAL; DIZZINESS; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DRY SKIN; DYSPLASIA; EMBASE; EMOTIONAL DISORDER; ENZYME ACTIVITY; ERYTHEMA; FACE ERYTHEMA; HEADACHE; HISTOPATHOLOGY; HUMAN; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INSOMNIA; LEUKOPLAKIA; MEDLINE; MOUTH CANCER; MOUTH PAIN; MYALGIA; NAUSEA; OUTCOME ASSESSMENT; PATIENT SATISFACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SKIN INJURY; SMOKING; SYSTEMATIC REVIEW; TOPICAL TREATMENT; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VISUAL DISORDER; WORLD HEALTH ORGANIZATION; XEROSTOMIA; LEUKOPLAKIA, ORAL; META ANALYSIS; MOUTH NEOPLASMS;

HUMANS; LEUKOPLAKIA, ORAL; MOUTH NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84979678857     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD001829.pub4     Document Type: Review

References (88)

1. Armstrong WB, Taylor TH, Kennedy AR, Melrose RJ, Messadi DV, Gu M, et al. Bowman Birk inhibitor concentrate and oral leukoplakia: a randomized phase IIb trial. Cancer Prevention Research (Philadelphia, Pa.) 2013;6:410-8.
2. Epstein JB, Wong FL, Millner A, Le ND. Topical bleomycin treatment of oral leukoplakia: a randomized double-blind clinical trial. Head & Neck 1994;16(6):539-44.
3. Hong WK, Endicott J, Itri LM, Doos W, Batsakis JG, Bell R, et al. 13-cis-retinoic acid in the treatment of oral leukoplakia. New England Journal of Medicine 1986;315(24):1501-5.
4. Li N, Sun Z, Han C, Chen J. The chemopreventive effects of tea on human oral precancerous mucosa lesions. Proceedings of the Society for Experimental Biology and Medicine 1999;220(4):218-24.
5. Mallery SR, Tong M, Shumway BS, Curran AE, Larsen PE, Ness GM, et al. Topical application of a mucoadhesive freeze-dried black raspberry gel induces clinical and histologic regression and reduces loss of heterozygosity events in premalignant oral intraepithelial lesions: results from a multicentered, placebo-controlled clinical trial. Clinical Cancer Research 2014;20(7):1910-24.
6. Mulshine JL, Atkinson JC, Greer RO, Papadimitrakopoulou VA, Van Waes C, Rudy S, et al. Randomized, double-blind, placebo-controlled phase IIb trial of the cyclooxygenase inhibitor ketorolac as an oral rinse in oropharyngeal leukoplakia. Clinical Cancer Research 2004;10(5):1565-73.
7. Nagao T, Warnakulasuriya S, Fukano H, Nakamura T, Kato S, Yamamoto K, et al. A randomized controlled trial for the treatment of oral leukoplakia with the aid of chemopreventive agents. Journal of Oral and Maxillofacial Surgery 2007;65(9 Suppl):41.e6.
8. Nagao T, Warnakulasuriya S, Fukano H, Suzuki K, Shimozato K, Hashimoto S. A randomised trial for preventing malignant transformation of oral leukoplakia. Oral Surgery 2010;3:103-14.
9. Nagao T, Warnakulasuriya S, Nakamura T, Kato S, Yamamoto K, Fukano H, et al. Treatment of oral leukoplakia with a low-dose of beta-carotene and vitamin C supplements: a randomized controlled trial. International Journal of Cancer 2015;136:1708-17.
10. Nagao T, Warnakulasuriya S, Sakuma H, Suzuki K, Hashimoto S. Is response to chemoprevention in oral leukoplakia determined by p53 expression?. Oral Diseases 2010;16:518.
11. Papadimitrakopoulou VA, William WN Jr, Dannenberg AJ, Lippman SM, Lee JJ, Ondrey FG, et al. Pilot randomized phase II study of celecoxib in oral premalignant lesions. Clinical Cancer Research 2008;14:2095-101.
12. Piattelli A, Fioroni M, Santinelli A, Rubini C. bcl-2 expression and apoptotic bodies in 13-cis-retinoic acid (isotretinoin)-topically treated oral leukoplakia: a pilot study. Oral Oncology 1999;35(3):314-20.
13. Sankaranarayanan R, Mathew B, Varghese C, Sudhakaran PR, Menon V, Jayadeep A, et al. Chemoprevention of oral leukoplakia with vitamin A and beta carotene: an assessment. Oral Oncology 1997;33(4):231-6.
14. Singh M, Krishanappa R, Bagewadi A, Keluskar V. Efficacy of oral lycopene in the treatment of oral leukoplakia. Oral Oncology 2004;40(6):591-6.
15. Stich HF, Hornby AP, Mathew B, Sankaranarayanan R, Nair MK. Response of oral leukoplakias to the administration of vitamin A. Cancer Letters 1988;40(1):93-101.
16. Sun Z, Guan X, Li N, Liu X, Chen X. Chemoprevention of oral cancer in animal models, and effect on leukoplakias in human patients with ZengShengPing, a mixture of medicinal herbs. Oral Oncology 2010;46:105-10.
17. Tsao AS, Liu D, Martin J, Tang XM, Lee JJ, El-Naggar AK, et al. Phase II randomized, placebo-controlled trial of green tea extract in patients with high-risk oral premalignant lesions. Cancer Prevention Research (Philadelphia, Pa.) 2009;2:931-41.
18. Bocharova OA, Pozharitskaya MM, Chekalina TL, Lyzhenkova MA, Karpova RV, Mezentseva MV, et al. Leukoplakia of oral mucosa: pathogenesis and possible correction with phytoadaptogen. Bulletin of Experimental Biology and Medicine 2004;138(6):578-83.
19. Boisnic S, Branchet MC, Pascal F, Ben Slama L, Rostin M, Szpirglas H. Topical tretinoin in the treatment of lichen planus and leukoplakia of the mouth mucosa. A clinical evaluation [Trétinoine topique dans le traitement des lichens plans et des leucoplasies de la muqueuse buccale. Evaluation clinique]. [French]. Annals of Dermatology and Venereology 1994;121(6-7):459-63.
20. Chee M, Sasaki C. Carbon dioxide laser fiber for the excision of oral leukoplakia. Annals of Otology, Rhinology, and Laryngology 2013;122:547-9.
21. Chiesa F, Tradati N, Grigolato R, Boracchi P, Biganzoli E, Crose N, et al. Randomized trial of fenretinide (4-HPR) to prevent recurrences, new localizations and carcinomas in patients operated on for oral leukoplakia: long-term results. International Journal of Cancer 2005;115(4):625-9.
22. Chiesa F, Tradati N, Marazza M, Rossi N, Boracchi P, Mariani L, et al. Fenretinide (4-HPR) in chemoprevention of oral leukoplakia. Journal of Cellular Biochemistry Supplement 1993;17F:255-61.
23. Chiesa F, Tradati N, Marazza M, Rossi N, Boracchi P, Mariani L, et al. Prevention of local relapses and new localisations of oral leukoplakias with the synthetic retinoid fenretinide (4-HPR). Preliminary results. European Journal of Cancer. Part B, Oral Oncology 1992;28B(2):97-102.
24. Costa A, Formelli F, Chiesa F, Decensi A, De Palo G, Veronesi U. Prospects of chemoprevention of human cancers with the synthetic retinoid fenretinide. Cancer Research 1994;54(7 Suppl):2032s-7s.
25. De Palo G, Veronesi U, Marubini E, Camerini T, Chiesa F, Nava M, et al. Controlled clinical trials with fenretinide in breast cancer, basal cell carcinoma and oral leukoplakia. Journal of Cellular Biochemistry Supplement 1995;22:11-7.
26. Femiano F, Gombos F, Scully C, Battista C, Belnome G, Esposito V. Oral leukoplakia: open trial of topical therapy with calcipotriol compared with tretinoin. International Journal of Oral and Maxillofacial Surgery 2001;30(5):402-6.
27. Gaeta GM, Gombos F, Femiano F, Battista C, Minghetti P, Montanari L, et al. Acitretin and treatment of the oral leucoplakias. A model to have an active molecules release. Journal of the European Academy of Dermatology and Venereology 2000;14(6):473-8.
28. Garewal H, Pitcock J, Friedman S, Alberts D, Meyskens F, Ramsey L, et al. Beta-carotene in oral leukoplakia. Proceedings, Annual Meeting of the American Society of Clinical Oncology 1992;11:141.
29. Garewal HS, Katz RV, Meyskens F, Pitcock J, Morse D, Friedman S, et al. Beta-carotene produces sustained remissions in patients with oral leukoplakia: results of a multicenter prospective trial. Archives of Otolaryngology - Head and Neck Surgery 1999;125(12):1305-10.
30. Krishnaswamy K, Prasad MP, Krishna TP, Annapurna VV, Reddy GA. A case study of nutrient intervention of oral precancerous lesions in India. European Journal of Cancer. Part B: Oral Oncology 1995;31B(1):41-8.
31. Lippman SM, Batsakis JG, Toth BB, Weber RS, Lee JJ, Martin JW, et al. Comparison of low-dose isotretinoin with beta carotene to prevent oral carcinogenesis. New England Journal of Medicine 1993;328(1):15-20.
32. Papadimitrakopoulou VA, Lippman SM, Lee JS, Toth BB, Martin JW, Lee JJ, et al. Long term follow-up of low-dose isotretinoin (13-cRA) versus beta carotene to prevent oral carcinogenesis. Proceedings, Annual Meeting of the American Society of Clinical Oncology 1996;15:A340.
33. 2 laser and cold knife: a randomized clinical trial. Medicina Oral, Patologia Oral y Cirugia Bucal 2013;18:38e-44e.
34. Mathew B, Sankaranarayanan R, Nair PP, Varghese C, Somanathan T, Amma BP, et al. Evaluation of chemoprevention of oral cancer with Spirulina fusiformis. Nutrition and Cancer 1995;24(2):197-202.
35. Schwarz F, Maraki D, Yalcinkaya S, Bieling K, Bocking A, Becker J. Cytologic and DNA-cytometric follow-up of oral leukoplakia after CO2- and Er:YAG-laser assisted ablation: a pilot study. Lasers in Surgery and Medicine 2005;37(1):29-36.
36. Zaridze D, Evstifeeva T, Boyle P. Chemoprevention of oral leukoplakia and chronic esophagitis in an area of high incidence of oral and esophageal cancer. Annals of Epidemiology 1993;3(3):225-34.
37. Califano JA, Ferris RL, Epstein JB, Gillespie MB, Feldman LE, Gibson MK, et al. A phase II trial of cetuximab in high-risk premalignant lesions of the upper aerodigestive tract. Journal of Clinical Oncology 2012;30(No 15_suppl (May 20 Suppl)):5528.
38. Chiba I, Takeshima M, Abiko Y, Kobayashi H, Muthumala M, Sugiura C, et al. Curcumin is an effective chemopreventive substance for betel quid chewer's oral precancer in Sri Lanka. Cancer Prevention Research 2012;5(11 Suppl 1):PR-04. [DOI: 10.1158/1940-6207.PREV-12-PR-04]
39. NCT00004161 Fenretinide in treating patients with leukoplakia of the mouth. https://clinicaltrials.gov/ct2/show/NCT00004161 (accessed 16 May 2016).
40. NCT00014404 Celecoxib in treating patients with precancerous lesions of the mouth. https://clinicaltrials.gov/ct2/show/NCT00014404 (accessed 16 May 2016).
41. NCT00101335 Celecoxib in preventing head and neck cancer in patients with oral leukoplakia. https://clinicaltrials.gov/ct2/show/NCT00101335 (accessed 16 May 2016).
42. NCT00155337 Photodynamic therapy for oral leukoplakia and erythroleukoplakia. https://clinicaltrials.gov/ct2/show/NCT00155337 (accessed 16 May 2016).
43. NCT00176566 A phase II trial to assess the effects of green tea in oral leukoplakia. https://clinicaltrials.gov/ct2/show/NCT00176566 (accessed 16 May 2016).
44. NCT00299195 A randomized study of sulindac in oral premalignant lesions. https://clinicaltrials.gov/ct2/show/NCT00299195 (accessed 16 May 2016).
45. NCT00402779 Erlotinib prevention of oral cancer (EPOC). https://clinicaltrials.gov/ct2/show/NCT00402779 (accessed 16 May 2016).
46. NCT00951379 Pioglitazone for oral premalignant lesions. https://clinicaltrials.gov/ct2/show/NCT00951379 (accessed 16 May 2016).
47. NCT01497951 Photodynamic therapy for oral precursor lesions (PDT). https://clinicaltrials.gov/ct2/show/NCT01497951 (accessed May 2016).
48. Abbey LM, Kaugars GE, Gunsolley JC, Burns JC, Page DG, Svirsky JA, et al. Intraexaminer and interexaminer reliability in the diagnosis of oral epithelial dysplasia. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontics 1995;80(2):188-91.
49. Arduino PG, Bagan J, El-Naggar AK, Carrozzo M. Urban legends series: oral leukoplakia. Oral Diseases 2013;19:642-59. [DOI: 10.1111/odi.12065]
50. Axell T, Holmstrup P, Kramer IRH, Pindborg JJ. International seminar on oral leukoplakia and associated lesions related to tobacco habits. Community Dentistry and Oral Epidemiology 1984;12:145-54.
51. Axell T. Occurrence of leukoplakia and some other oral white lesions among 20, 333 adult Swedish people. Community Dentistry and Oral Epidemiology 1987;15(1):46-51.
52. Axell T, Pindborg JJ, Smith CJ, Van der Waal I. Oral white lesions with special reference to precancerous and tobacco-related lesions: conclusions of an international symposium held in Uppsala, Sweden, May 18-21, 1994. International Collaborative Group on Oral White Lesions. Journal of Oral Pathology & Medicine 1996;25(2):49-54. [MEDLINE: 1996237276]
53. Bouquot JE, Gorlin RJ. Leukoplakia, lichen planus, and other oral keratoses in 23, 616 white Americans over the age of 35 years. Oral Surgery, Oral Medicine and Oral Pathology 1986;61(4):373-81.
54. Dietrich T, Reichart PA, Scheifele C. Clinical risk factors of oral leukoplakia in a representative sample of the US population. Oral Oncology 2004;40(2):158-63.
55. Epstein JB, Thariat J, Bensadoun RJ, Barasch A, Murphy BA, Kolnick L, et al. Oral complications of cancer and cancer therapy: from cancer treatment to survivorship. CA: A Cancer Journal for Clinicians 2012;62:400-22.
56. Gupta PC, Mehta FS, Daftary DK, Pindborg JJ, Bhonsle RB, Jalnawalla PN, et al. Incidence rates of oral cancer and natural history of oral precancerous lesions in a 10-year follow-up study of Indian villagers. Community Dentistry and Oral Epidemiology 1980;8(6):283-33.
57. Higgins JPT, Deeks JJ, Altman DG, on behalf of the Cochrane Statistical Methods Group. Chapter 16: Special topics in statistics. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. Chichester, UK: John Wiley & Sons, Ltd, 2011.
58. Higgins JPT, Deeks JJ, Altman DG, on behalf of the Cochrane Statistical Methods Group. Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. Chichester, UK: John Wiley & Sons, Ltd, 2011.
59. Holmstrup P, Vedtofte P, Reibel J, Stoltze K. Long-term treatment outcome of oral premalignant lesions. Oral Oncology 2006;42(5):461-74.
60. Holmstrup P. Can we prevent malignancy by treating premalignant lesions?. Oral Oncology 2009;45:549-50.
61. Ikeda N, Ishii T, Iida S, Kawai T. Epidemiological study of oral leukoplakia based on mass screening for oral mucosal diseases in a selected Japanese population. Community Dentistry and Oral Epidemiology 1991;19(3):160-3.
62. Karabulut A, Reibel J, Therkildsen MH, Praetorius F, Nielesen HW, Dabelsteen E. Observer variability in the histologic assessment of oral premalignant lesions. Journal of Oral Pathology Medicine 1995;24(5):198-200.
63. Kramer IR, Lucas RB, Pindborg JJ, Sobin LH. Definition of leukoplakia and related lesions: an aid to studies on oral precancer. Oral Surgery, Oral Medicine and Oral Pathology 1978;46(4):518-39. [MEDLINE: 1979053956]
64. Lind PO. Malignant transformation in oral leukoplakia. Scandinavian Journal of Dental Research 1987;95(6):449-55.
65. Lodi G, Porter S. Management of potentially malignant disorders: evidence and critique. Journal of Oral Pathology & Medicine 2008;37:63-9.
66. Lumerman H, Freedman P, Kerpel S. Oral epithelial dysplasia and the development of invasive squamous cell carcinoma. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontics 1995;79(3):321-9.
67. Marley JJ, Cowan CG, Lamey PJ, Linden GJ, Johnson NW, Warnakulasuriya KA. Management of potentially malignant oral mucosal lesions by consultant UK oral and maxillofacial surgeons. British Journal of Oral and Maxillofacial Surgery 1998;34(1):28-36.
68. Nagao T, Ikeda N, Fukano H, Hashimoto S, Shimozato K, Warnakulasuriya S. Incidence rates for oral leukoplakia and lichen planus in a Japanese population. Journal of Oral Pathology and Medicine 2005;34(9):532-9.
69. Petti S. Pooled estimate of world leukoplakia prevalence: a systematic review. Oral Oncology 2003;39:770-80.
70. Pitiyage G, Tilakaratne WM, Tavassoli M, Warnakulasuriya S. Molecular markers in oral epithelial dysplasia: review. Journal of Oral Pathology & Medicine 2009;38:737-52.
71. Reichart PA. Oral mucosal lesions in a representative cross-sectional study of aging Germans. Community Dentistry and Oral Epidemiology 2000;28(5):390-8.
72. Saito T, Sugiura C, Hirai A, Notani K, Totsuka Y, Shindoh M, et al. Development of squamous cell carcinoma from pre-existent oral leukoplakia: with respect to treatment modality. International Journal of Oral and Maxillofacial Surgery 2001;30(1):49-53.
73. Scheifele C, Reichart PA. Is there a natural limit of the transformation rate of oral leukoplakia?. Oral Oncology 2003;39(5):470-5.
74. Schepman KP, van der Meij EH, Smeele LE, van der Waal I. Malignant transformation of oral leukoplakia: a follow-up study of a hospital-based population of 166 patients with oral leukoplakia from The Netherlands. Oral Oncology 1998;34(4):270-5.
75. Scully C, Bagan J. Oral squamous cell carcinoma overview. Oral Oncology 2009;45:301-8.
76. Shiu MN, Chen TH, Chang SH, Hahn LJ. Risk factors for leukoplakia and malignant transformation to oral carcinoma: a leukoplakia cohort in Taiwan. British Journal of Cancer 2000;82(11):1871-4.
77. Silverman S Jr, Gorsky M, Lozada F. Oral leukoplakia and malignant transformation. A follow-up study of 257 patients. Cancer 1984;53(3):563-8.
78. Smith J, Rattay T, McConkey C, Helliwell T, Mehanna H. Biomarkers in dysplasia of the oral cavity: a systematic review. Oral Oncology 2009;45:647-53.
79. Sperandio M, Brown AL, Lock C, Morgan PR, Coupland VH, Madden PB, et al. Predictive value of dysplasia grading and DNA ploidy in malignant transformation of oral potentially malignant disorders. Cancer Prevention Research (Philadelphia, Pa.) 2013;6:822-31.
80. Syrjänen S, Lodi G, von Bültzingslöwen I, Aliko A, Arduino P, Campisi G, et al. Human papillomaviruses in oral carcinoma and oral potentially malignant disorders: a systematic review. Oral Diseases 2011;17 Suppl 1:58-72.
81. Torres-Rendon A, Stewart R, Craig GT, Wells M, Speight PM. DNA ploidy analysis by image cytometry helps to identify oral epithelial dysplasias with a high risk of malignant progression. Oral Oncology 2009;45:468-73.
82. Van der Waal I. Potentially malignant disorders of the oral and oropharyngeal mucosa; terminology, classification and present concepts of management. Oral Oncology 2009;45:317-23.
83. Warnakulasuriya S, Johnson NW, Van der Waal I. Nomenclature and classification of potentially malignant disorders of the oral mucosa. Journal of Oral Pathology & Medicine 2007;36:575-80.
84. Warnakulasuriya S, Kovacevic T, Madden P, Coupland VH, Sperandio M, Odell E, et al. Factors predicting malignant transformation in oral potentially malignant disorders among patients accrued over a 10-year period in South East England. Journal of Oral Pathology & Medicine 2011;40:677-83.
85. Worthington H, Clarkson J, Weldon J. Priority oral health research identification for clinical decision-making. Evidence-based Dentistry 2015;16(3):69-71.
86. Lodi G, Sardella A, Bez C, Demarosi F, Carrassi A. Systematic review of randomized trials for the treatment of oral leukoplakia. Journal of Dental Education 2002;66(8):896-902.
87. Lodi G, Sardella A, Bez C, Demarosi F, Carrassi A. Interventions for treating oral leukoplakia. Cochrane Database of Systematic Reviews 2004, Issue 3. [DOI: 10.1002/14651858.CD001829.pub2]
88. Lodi G, Sardella A, Bez C, Demarosi F, Carrassi A. Interventions for treating oral leukoplakia. Cochrane Database of Systematic Reviews 2006, Issue 4. [DOI: 10.1002/14651858.CD001829.pub3]